Floatz logo

Duvelisib

Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Inno-206
Eric Jacobsen, MD
Phase 2B
Cerdulatinib
Portola Pharmaceuticals
Phase 2/3CCC

View all 20 →

Same molecule, other indications

Duvelisib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
60 / 100
View asset →
follicular lymphomaDormant
B
Indicative ·
56 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →